Objective To analyse the risk factors of hepatocellular carcinoma（HCC）recurrence after liver transplantation and to build a logistic regression model to predict HCC recurrence which helps patient's selection. Methods A total number of 173 patients diagnosed with HCC and received liver transplantation were enrolled in the research. Univariate and multivariate Cox analysis were used to explore the risk factors of HCC recurrence after liver transplantation， logistic regression was used to build a scoring model. Results Univariate andmultivariate Cox regression analysis showed that plasma fibrinogen concentration， macrovascular invasion， total tumorvolume ＞ 115 cm3 and alpha fetoprotein（AFP）＞ 400 ng/ml were independent risk factors of HCC recurrence afterliver transplantation. The logistic regression model was， Y ＝ logit（P）＝ -3.047 + 0.699 × fibrinogen concentration + 1.568× TTV ＞ 115 cm3 （0 ＝ no，1 ＝ yes） + 0.317×macrovascular invasion （0 ＝ no，1 ＝ yes） + 1.6× AFP ＞ 400 ng/ml（0 ＝ no，1 ＝ yes）. The sensitivity and specificity in predicting HCC recurrence were 86.6% and 65.8%. The area under receiver operating characteristic （ROC） curve was 0.800， compared with 0.687 of Milan criteria and 0.703 of Hangzhou criteria. The 5-year RFS of patients with model score Y ≤ -0.79 was significantly higher thanpatients with Y ＞ -0.79（92.3% vs. 34.1%，P ＜ 0.001）. Within patients who meet Milan and Hangzhou criteria，the 5-year RFS of patients with Y ≤ -0.79 was also significantly higher than patients with Y ＞ -0.79（94.9% vs. 40.9%，P ＜ 0.001；93.6% vs. 45.7%，P ＜ 0.001，respectively）. ConclusionPlasma fibrinogen concentration，macrovascular invasion， total tumor volume ＞ 115 cm3 and AFP＞ 400ng/ml were independent risk factors of HCC recurrence after liver transplantation. The logistic regression models we built was sensitive and specific in predicting HCC recurrence after liver transplantation.

Objective To discuss the clinical application value of locoregional therapy in livertransplantation for hepatocellular carcinoma in China. Methods We retrospectively reviewed the data of1 739 transplantation recipients registered in the China Liver Transplant Registry（CLTR）till October 2016 who suffered from hepatocellular carcinoma. The utilization of locoregional therapy was summarized，and its influence on the survival of transplantation recipients was analyzed. Results A total of 563 cases met the Milan criteria，234 cases received pre-transplantationlocoregional therapy. The 1-year，3-year and 5-year overall survival rate ofthe patients in the Milan criteria group were 88.66%，76.29% and 67.02%，respectively. While the 1-year，3-year and 5-year overall survival rate of the patients in the locoregional therapy group were 78.33%，40.77% and 29.12%，respectively. The 1-year，3-year overall survival of patients with AJCC Stage Ⅰ - Ⅱ tumors were 85.14% and 60.95%，which was similar to the survival of the patients in the Milan criteria group（P ＝ 0.12）. Radiofrequency ablation，transcatheterarterial chemoembolization，and multimodality therapy were used in 36.5%，47.0%，15.82%patients of the locoregional therapy group. The survival of patients who received these three treatment showed nodifference（P ＝ 0.352）. Conclusion Pre-transplantation locoregional therapy have been widely used. Patientswho exceed the Milan criteria but within the AJCC stage Ⅱ were still good candidates for liver transplantation.The effect of radiofrequency ablation，transcatheter arterial chemoembolization，and multimodality therapy were equivalent in the pre-transplantation therapy.

Objective To study the value of liver transplantation in the treatment of non-hepatocellularcarcinoma （HCC） malignant liver tumors. Methods The data of 40 adult patients with non-HCC malignancy who underwent liver transplantation were retrospectively analyzed. Among them, 23 cases were intrahepatic cholangiocarcinoma and 2 cases were hepatblastoma. There was 1 case of fibrous lamellar hepatocellularcarcinoma. One case of malignant hemangioma. Two cases of hepatic epithelioid hemangioendothelioma. One case of hepatic angiosarcoma. Multiple low differentiated soft tissue angiosarcoma of the liver was seen in 1 case. Metastatic adenocarcinoma was seen in 4 cases, colorectal cancer metastasis was seen in 3 cases, bladdercancer metastasis was seen in 1 case. Neuroendocrine tumors metastases was seen in 2 cases. There were 2 cases of liver metastases from gastrointestinal stromal tumors. Small cell lymphoma liver involvement was seen in 1 case. Results Of the 23 patients with cholangiocarcinoma, one died of severe intrahepatic infection.Recurrence occurred in 12 patients. One case of hepatblastoma died of recurrence. The other one survived without tumor. 1 case of fibrous lamellar hepatocellular carcinoma died of tumor recurrence. One case of malignant hemangioperangioma died after operation. There were 2 cases of epithelioid hemangioendothelioma, 1 case died during perioperative period, and 1 case survived without tumor. Two cases of hepatic sarcoma recurred and died. Three cases were liver metastases from colorectal cancer and 1 case survived without tumor. One case of liver metastases from bladder cancer recurred and died. Two cases of liver metastases from neuroendocrine tumors survived. There were 2 cases of liver metastases from gastrointestinal stromal tumors, 1 case died during perioperative period, and 1 case survived. Conclusion Some patients with cholangiocarcinoma, hepatoblastoma, epithelioid hemangioendothelioma, neuroendocrine tumor, liver metastasis and gastrointestinal stromal tumors have good results after liver transplantation. However, some cholangiocarcinoma, partial hepatoma and sarcoma of liver have poor prognosis.

Objective To explore the risk factors affecting the survival rate of reintubation after liver transplantation，and to provide practical experience and theoretical basis for improving the survival rate of patients.Methods A retrospective analysis was performed on patients who underwent orthotopic liver transplantation in our hospital from January 2005 to December 2012. The patient's survival was calculated within three months after surgery. According to the survival condition at three months after operation，they were divided into survival groupand death group. The preoperative，intraoperative and donor liver parameters were compared between the two groups. The survival rate was used as the dependent variable. The included variables were analyzed by single factorand multivariate regression analysis，and the independent variables with significant influence on survival rate were selected. Results The survival rate of 55 patients with reintubation was 30.9%（17/55）. Preoperative model forend-stage liver disease（MELD）score（U ＝ 52.00，P ＜ 0.001），international normalized ratio（U ＝ 167.50，P ＜ 0.001），serum total bilirubin value（U ＝ 191.00，P ＝ 0.016），incidenceofpulmonaryinfection complicationin the death group（χ2 ＝5.30，P＝0.001）and theincidence ofascites complication（χ2 ＝ 5.33，P ＝ 0.001）were significantly higher than in the survival group. Age，preoperative serum creatinine level，portal vein thrombosis rate，incidence of pleural effusion，length of liver transplantation surgery，duration of anhepatic period，intraoperative blood loss，blood transfusion，warm ischemia time of donor liver and cold ischemia time were not statistical different. Regression analysis showed that the pulmonary infection comorbidity and MELD score remained in the logistic regression equation（OR ＝ 6.157，P ＝ 0.042 ；OR ＝ 1.312，P ＜0.001）were independent risk factors that affects the survival rate of reintubation. Conclusion For liver transplant recipients，preoperative MELD scoreand pulmonary infection comorbidity are independent risk factors for the survival rate of secondary tracheal intubation in the early postoperative period. Active control of pulmonary infection before surgery and efforts to reduce MELDscores can help improve survival.

Objective To discuss the experience of diagnosis and treatment for the patients with recurrenthepatocellular carcinoma （HCC） long-term after liver transplantation. Methods The clinical data were retrospectively analyzed from 1 308 HCC patients who received liver transplantation from April 2001 to September 2018 in Liver Cancer Institute, Fudan University. Close laboratory examination and radiological follow-up wereperformed post-transplantation. Results There were 2 patients with metastasis of HCC 10 years after liver transplantation. The patients' condition was satisfactorily controlled by comprehensive treatment strategy and one patient got complete response. Conclusion LT is one of the radical treatments for HCC, however，tumor recurrence and metastasis remain the most important factors that affect the outcome of liver transplantation. Screening the recipients properly, selecting the sensitive factors which can accurately predict the prognosis after liver transplantation,offering effective intervention for patients at high risks of recurrence and providing individualized treatment after recurrence and metastasis may further improve the outcome of LT with HCC.

Objective To summary and discuss the successful diagnosis and therapy to antibody mediatedrejection（AMR）post pediatric ABO-incompatible liver transplantation. Methods Abnormal graft function was found within 1 month after living donor liver transplantation. Then，liver biopsy were performed twice and human lymphocyte antigen（HLA）antibodies were detected. Results Acute rejection was revealed in both liver biopsies，intravenous methylprednisolone was used for anti-rejection therapy. AMR was diagnosed by positivity of C4d and strong expression of donor specific antibody（DSA）subsequently. The effective therapies were performedincluding combination of plasmapheresis and intravenous immunoglobulin（IVIG）on alternate days for 1 week，followed by single rituximab. Meanwhile，mycophenolate mofetil was used at the beginning. The graft function recovered to normal with decreasing of DSA. The patient has been followed for more than 2 years with well graftfunction. Conclusion AMR could be induced by ABO incompatible pediatric liver transplantation with serious consequence. AMR can be cured by conservative therapies and normal graft function could be achieved.